Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) Stock Information | RedChip

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS)


$4.5300
-0.4600 ( -8.49% ) 612.3K

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Market Data


Open


$4.5300

Previous close


$4.9900

Volume


612.3K

Market cap


$302.65M

Day range


$4.5300 - $5.0070

52 week range


$1.3000 - $10.0000

SEC Filings


Form Type Description Pages Date
8-k 8K-related 19 Dec 18, 2024
10-q Quarterly Reports 77 Nov 12, 2024
8-k 8K-related 15 Nov 12, 2024
8-k 8K-related 14 Oct 23, 2024
10-q Quarterly Reports 76 Aug 06, 2024
8-k 8K-related 16 Aug 06, 2024
4 Insider transactions 1 Jun 17, 2024
4 Insider transactions 1 Jun 17, 2024
4 Insider transactions 1 Jun 17, 2024
4 Insider transactions 1 Jun 17, 2024

Latest News